Disclosure Plus

SEOHEE CONSTRUCTION CO., LTD. Decides to Cancel 46.5 Billion Won Worth of Treasury Stock

Park Sun-Yeop
2026-07-03 12:28:21
[Edaily Reporter Park Sun-Yeop ] SEOHEE CONSTRUCTION CO., LTD.(035890)announced on the 3rd that it has decided to cancel 22,219,921 shares of treasury stock it had previously acquired in order to enhance shareholder value and restore market confidence.
The estimated cost of the cancellation is 46.55073 billion won. This amount is calculated based on the closing price of 2,095 won on the 2nd, the day before the board of directors’ resolution. As of the date of the board resolution, the book value of the treasury shares held directly by the company and subject to cancellation is 29.66844 billion won.
The shares to be retired account for approximately 9.7% of the total number of issued shares—229,808,457 shares—prior to the retirement. Upon completion of the retirement, the total number of issued shares is expected to decrease to 207,588,536 shares.
This share cancellation involves the cancellation of previously acquired treasury shares, as resolved by the board of directors, within the scope of distributable earnings. Accordingly, only the total number of issued shares will decrease; there will be no reduction in capital stock. The scheduled date for the cancellation is the 15th of this month.

Economy

Corporation

IT·Science

Economy

NEXTBIOMEDICAL CO., LTD., Which Made Its Mark Globally with NexPowder, Named a “KOSDAQ Rising Star” for the Second Consecutive Year

#NEXTBIOMEDICAL CO., LTD., a company specializing in innovative medical devices, has been named to the Korea Exchange’s “KOSDAQ Rising Star” list for the second consecutive year, once again demonstrat…
2026-08-19 10:02:44

Corporation

Celltrion, Buoyed by Direct Sales, Expands into Asia’s Pharm-Emerging Markets... Solidifies No. 1 Position and Prepares New Drugs

Celltrion(068270)Celltrion is strengthening its market dominance in Asia—a leading “Shinhung” (emerging pharmaceutical) market—by leveraging its unrivaled direct-to-market competitiveness. While its f…
2026-08-19 09:54:02

IT·Science

LGCHEM,LTD Begins Preclinical Trials for ‘GNV205,’ an Immunotherapy Drug Based on Genube Technology

# LGCHEM,LTD is set to begin preclinical research on “GNV205,” an antibody-cytokine fusion candidate acquired from the domestic biotech firm GenuV. The company plans to develop it as a next-gen…
2026-08-19 10:20:03